

Table 5. Summary of overall colposcopy outcome: eligibility, compliance and efficacy from cumulative data from round-1 screening and repeat testing on subgroup of women tested positive for HPV-12 others at 12 months.

	Age Grouping, years					Total	HPV typing			Total
	<30	30-39	40-49	50-59	≥60		HPV-16	HPV-18	HPV-12 others	
Overall (n) <sup>a</sup>	913	2642	2918	2612	1598	10683	136	56	491	683
<b>Colposcopy recommended (cumulative number including repeat test at 12 months)</b>										
No. of cases	80	156	117	59	60	472	136	56	280	472
%	8.8	5.9	3.0	2.3	3.8	4.4	100	100	57.1	69.1
Difference between groups	<i>P</i> <0.00001 <sup>b</sup>					Not applicable				
<b>Colposcopy performed</b>										
No. of cases	77	128	95	49	42	391	136	56	199	391
%	96.3	82.1	81.2	83.1	70	82.8	100	100	71.1	82.8
Difference between groups	<i>P</i> =0.0016 <sup>b</sup>					Not applicable				
<b>No. of colposcopy per CIN2+ case</b>										
	11	18.5	7.9	12.3	14	9.5	6.5	18.7	11.7	9.5
Difference between groups	<i>P</i> =0.8062 <sup>b</sup>					<i>P</i> =0.051 <sup>b</sup>				
<b>No. of colposcopy per CIN3+ case</b>										
	38.5	10.7	8.6	12.3	21	12.6	8.5	18.7	16.6	12.6
Difference between groups	<i>P</i> =0.2244 <sup>b</sup>					<i>P</i> =0.1205 <sup>b</sup>				
Difference between subgroups	<i>P</i> =0.053 <sup>b</sup> Subgroup: age <30 years versus ≥30 years					<i>P</i> =0.040 <sup>b</sup> Subgroup: HPV-16 versus Other HPVs				

<sup>a</sup> Overall number excluded 284 women who defaulted repeat HPV DNA testing at 12-months follow-up.

<sup>b</sup>  $\chi^2$ -test